Today: 30 June 2026
CrowdStrike stock fell 3% Friday — what to watch before markets reopen
5 January 2026
1 min read

CrowdStrike stock fell 3% Friday — what to watch before markets reopen

NEW YORK, January 4, 2026, 18:48 ET — Market closed

  • CrowdStrike shares ended the first U.S. session of 2026 down about 3%, closing at $453.58.
  • Cybersecurity peers also weakened even as the S&P 500 edged higher.
  • Traders are watching near-term support around the $450 area ahead of key U.S. jobs data later this week.

CrowdStrike Holdings, Inc. (CRWD) shares fell 3.2% on Friday to close at $453.58, trading between $449.49 and $477.25 as the cybersecurity stock lagged the broader market’s first session of 2026. Volume was about 3.3 million shares.

The slide matters heading into Monday because early January trading often sets the tone for positioning after year-end, especially in high-valuation software where small shifts in sentiment can move prices quickly.

U.S. stocks eked out small gains on Friday in a choppy start to the year, with technology names driving much of the up-and-down action, the Associated Press reported. The S&P 500 rose 0.2%, while the Nasdaq ended roughly flat.

Cybersecurity shares were broadly softer. Palo Alto Networks fell 2.6% and Fortinet dropped 1.9%, while Cisco edged lower, MarketWatch data showed.

CrowdStrike sells subscription-based protection through its Falcon platform. Investors track annual recurring revenue (ARR) — the annualized value of subscriptions — because it offers an early read on whether customers are expanding security spend.

In its last major update, CrowdStrike projected fourth-quarter revenue of $1.29 billion to $1.30 billion and raised its full-year revenue outlook to $4.80 billion to $4.81 billion, citing rising adoption of AI-integrated tools, Reuters reported.

A Dec. 2 filing said CrowdStrike’s fiscal fourth quarter and full year end on Jan. 31, 2026. The company reported its prior fiscal year results on March 4, 2025, and it has not yet announced the date for its next earnings release.

On the chart, the close near the bottom of Friday’s range puts the $450 area in focus as near-term support — a price zone where sellers previously struggled to push the stock lower — while the high $470s mark the first resistance band if buyers step back in.

Macro risk sits on top of stock-specific catalysts. Reuters’ weekly “Take Five” note flagged the next installment of U.S. jobs data on Jan. 9 as an early-year focal point for rate expectations, and said a Reuters poll forecasts 55,000 jobs were created in December. Reuters

Joe Mazzola, head of trading and derivatives strategy at Charles Schwab, described a “buy the dip, sell the rip” mindset, while cautioning that investors are paying closer attention to the valuations they pay for some AI-linked trades. Reuters

But CrowdStrike has little room for a stumble if the market keeps questioning high-multiple software. The company has said incentive programs and discounts tied to the July 2024 outage have weighed on the timing of subscription revenue, a dynamic that can muddy near-term growth signals even when demand holds up.

The next scheduled catalyst is the U.S. Employment Situation report for December, due at 8:30 a.m. ET on Jan. 9, a Labor Department calendar shows.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop